Mitochondrial myopathies and encephalomyopathies

European Journal of Clinical Investigation

Volumn 29, Issue 10, 1999, Pages 886-898

  Schapira, A H V ^a,b   Cock, H R ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CELL NUCLEUS DNA; FREE RADICAL; MITOCHONDRIAL DNA; PROTEIN SUBUNIT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BASE PAIRING; DEGENERATIVE DISEASE; ELECTRON TRANSPORT; ENCEPHALOMYOPATHY; FRIEDREICH ATAXIA; GENE MUTATION; GENOTYPE; HEREDITARY MOTOR SENSORY NEUROPATHY; HEREDITARY OPTIC ATROPHY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; KEARNS SAYRE SYNDROME; LEIGH DISEASE; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; MYOCLONUS EPILEPSY; OPHTHALMOPLEGIA; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL;

DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIAL ENCEPHALOMYOPATHIES; MITOCHONDRIAL MYOPATHIES; OXIDATIVE PHOSPHORYLATION; POINT MUTATION;

EID: 0032885238     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00540.x     Document Type: Article

References (116)

1. 1 Harding AE, Hammans SR. Deletions of the mitochondrial genome. J Inher Metab Dis, 1992;15:480-6.
2. 2 Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia and complete heart block. Ophthalmology 1958;60:280-9.
3. 3 DiMauro S, Bonilla E, Zeviani M, Nakagawa M, De Vivo DC. Mitochondrial myopathies. Ann Neurol 1985; 17:521-38.
4. 4 Rowland LP, Hausmanowa-Petrusewicz I, Barduska B, et al. Kearns-Sayre syndrome in twins: lethal dominant mutation or acquired disease? Neurology 1988;38:1399-402.
5. 5 Holt IJ, Harding AE, Cooper JM, et al. Mitochondrial myopathies: Clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Ann Neurol 1989;26:699-708.
6. 6 Bresolin N, Moggio M, Bet L, et al. Progressive cytochrome c oxidase deficiency in a case of Kearns-Sayre syndrome: Morphological,immunological and biochemical studies in muscle biopsies and autopsy tissues. Ann Neurol 1987;21:564-72.
7. 7 Moraes CT, DiMauro S, Zeviani M, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med 1989;320:1293-9.
8. 8 Carry MR, Ringel SP, Starcevich JM. Mitochondrial morphometrics of histochemically defined identified human extraocular muscles. Anat Rec 1986;214:8-16.
9. 9 Zeviani M, Moraes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988;38:1339-46.
10. 10 Fassati A, Bordoni A, Amboni P, et al. Chronic progressive external ophthalmoplegia: a correlative study of quantitative molecular data and histochemical and biochemical profile. J Neurol Sci 1994;123:140-6.
11. 11 Shanske S, Moraes CT, Lombes A, et al. Widespread tissue distribution of mitochondrial DNA deletions in Kearns-Sayre syndrome. Neurology 1990;40:24-8.
12. 12 Pearson HA, Lobel JS, Kocoshis SA, et al. A new syndrome of refractory sideroblastic anaemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr 1979;95:976-84.
13. 13 Rötig A, Cormier V, Blanche S, et al. Pearson's marrow-pancreas syndrome: a multisystem mitochondrial disorder in infancy. J Clin Invest 1990;86:1601-8.
14. 14 McShane MA, Hammans SR, Sweeney M, et al. Pearson syndrome and mitochondrial encephalomyopathy in a patient with a deletion of mtDNA. Am J Hum Genet 1991;48:39-42.
15. 15 Bernes SM, Bacino C, Prezant TR, et al. Identical mitochondrial DNA deletion in mother with progressive external ophthalmoplegia and son with Pearson marrow-pancreas syndrome. J Pediatr 1993;123:598-602.
16. 16 Zeviani M, Servidei S, Gellera C, Bertini E, DiMauro S, DiDonato S. An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature 1989;339:309-11.
17. 17 Servidei S, Zeviani M, Manfredi G, et al. Dominantly inherited mitochondrial myopathy with multiple deletions of mitochondrial DNA. Neurology 1991;41:1053-9.
18. 18 Suomalainen A, Majander A, Haltia M, et al. Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalomoplegia. J Clin Invest 1992;90:61-6.
19. 19 Suomalainen A, Kaukonen J, Amati P, et al. An autosomal dominant locus predisposing to deletions of mitochondrial DNA. Nature Genet 1995;9:146-51.
20. 20 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
21. 21 Carrozzo R, Hirano M, Fromenty B, et al. Multiple mtDNA deletions features in autosomal dominant and recessive diseases suggest distinct pathogeneses. Neurology 1998;50:99-106.
22. 22 Hirano M, Garcia-d, e-Yebenes J, et al. Mitochondrial neurogastrointestinal encephalomyopthy syndrome maps to chromosome 22q13.32-qter. Am J Hum Genet 1998; 63:526-33.
23. 23 Nishino I, Spinazzola A, Hirano A. thymidine phosphorylase gene mutations in MNGIE. a human mitochondrial disorder. Science 1999;283:689-92.
24. 24 Mizusawa H, Watanabe M, Kanazawa I, et al. Familial mitochondrial myopathy associated with peripheral neuropathy: partial deficiences of complex I and IV. J Neurol Sci 1988;86:171-84.
25. 25 Yuzaki M, Ohkoshi N, Kanazawa I, Kagawa Y, Ohta S. Multiple deletions in mitochondrial DNA at direct repeats of non-D-loop regions in cases of familial mitochondrial myopathy. Biochem Biophys Res Commun 1989;164:1352-7.
26. 26 Cormier V, Rötig A, Tardieu M, Colonna M, Saudubray J, Munnich A. Autosomal dominant deletions of the mitochondrial genome in a case of progressive encephalomyopathy. Am J Hum Genet 1991;48:643-8.
27. 27 Moraes CT, Shanske S, Tritschler H, et al. MtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet 1991;48:492-501.
28. 28 Tritschler H, Andreetta F, Moraes CT, et al. Mitochondrial myopathy of childhood onset associated with depletion of mitochondrial DNA. Neurology 1992;42:209-17.
29. 29 Bodnar AG, Cooper JM, Holt IJ, Leonard JV, Schapira AHV. Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion. Am J Hum Genet 1993;53:663-9.
30. 30 Poulton J, Sewry C, Potter CG, et al. Variation in mitochondrial DNA levels in muscle from normal controls. Is depletion of mtDNA in patients with mitochondrial myopathy a distinct clinical syndrome?. J Inher Metab Dis 1995;18:4-20.
31. 31 Ricci E, Moraes CT, Servidei S, Tonali P, Bonilla E, DiMauro S. Disorders associated with depletion of mitochondrial DNA. Brain Pathol 1992;2:141-7.
32. 32 Poulton J, Morten K, Freeman-Emmerson C, et al. Deficiency of the human mitochondrial transcription factor h-MtTFA in infantile mitochondrial myopathy is associated with mtDNA depletion. Hum Mol Genet 1994;3:1763-9.
33. 33 Ballinger SW, Shoffner JM, Gebhart S, Koontz DA. Maternally transmitted diabetes and deafness associated with a 10.4kb mitochondrial DNA deletion. Nature Genet 1992;1:11-5.
34. 34 Holt IJ, Harding AE, Petty RKH, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990;46:428-33.
35. 35 Tatuch Y, Christodoulou J, Feigenbaum A, et al. Heteroplasmic mtDNA mutations (T_13Monotype SortsG) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high. Am J Hum Genet 1992;50:852-8.
36. 36 Ortiz RG, Newman NJ, Shoffner JM, Kaufman AE, Koontz DA, Wallace DC. Variable retinal and neurologic manifestations in patients harbouring the mitochondrial DNA 8993 mutation. Arch Ophthalmol 1993;111:1525-30.
37. 37 Santorelli FM, Mak B, Thyagarajan D, et al. Clinical heterogeneity of the nt 8993 point mutations in the mitochondrial DNA. Neurology 1995;45:A400.
38. 38 Willems JL, Monnens LAH, Trijbels JMF, et al. Leigh's encephalomyopathy in a patient with cytochrome c oxidase deficiency in muscle tissue. Pediatrics 1977;60:850-7.
39. 39 Davis PC, Hoffman JC, Braun IF, Anmann P, Krawiecki N. MR of Leigh's disease (subacute necrotising encephalomyopathy). Am J Neuroradiol 1987;8:71-5.
40. 40 Shepherd IM, Birch-Machin MA, Johnson MA, et al. Cytochrome oxidase deficiency: immunological studies of skeletal muscle mitochondrial fractions. J Neurol Sci 1988;87:265-74.
41. 41 Santorelli FM, Shanske S, Macaya A, De Vivo DC, DiMauro S. The mutation at nt8993 of mitochondrial DNA is a common cause of Leigh's syndrome. Ann Neurol 1993;34:827-34.
42. 42 Brown GK, Otero LJ, LeGris M, Brown RM. Pyruvate dehydrogenase deficiency. J Med Genet 1994;31:875-9.
43. 43 Kretzschmar HA, DeArmond SJ, Koch TK, et al. Pyruvate dehydrogenase complex deficiency as a cause of subacute necrotizing encephalopathy (Leigh disease). Pediatrics 1987;79:370-3.
44. 44 Miranda AF, Ishii S, DiMauro S, Shay JW. Cytochrome c oxidase deficiency in Leigh's syndrome: genetic evidence for a nuclear DNA encoded mutation. Neurology 1989;39:697-702.
45. 0 transformants. Hum Mol Genet 1995;4:2017-23.
46. 46 Adams PL, Lightowlers RN, Turnbull DM. Molecular analysis of cytochrome c oxidase deficiency in Leigh's syndrome. Ann Neurol 1997;41:268-70.
47. 47 Zhu Z, Yao J, Johns T, et al. SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nature Genet 1998;20: 337-43.
48. 48 Tiranti V, Hoertnagal K, Carrozzo R, et al. Mutations of SURF-1 in Leighj disease associated with cytochrome c oxidase deficiency. Am J Hum Genet 1998;63:1609-21.
49. 49 Berkovic SF, Carpenter S, Evans A, et al. Myoclonus epilepsy and ragged-red fibres (MERRF). Brain 1989;112:1231-60.
50. 50 Shoffner JM, Fernhoff PM, Krawiecki NS, et al. Subacute necrotizing encephalomyopathy: Oxidative phosphorylation defects and the ATPase 6 point mutation. Neurology 1992;42:2168-74.
51. 51 Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: a distinctive clinical syndrome. Ann Neurol 1984;16:481-8.
52. 52 Goto Y, Horai S, Matsuoka T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 1992;42:545-50.
53. 53 Koga Y, Nonaka I, Kobayashi M, Tojyo M, Nihei K. Findings in muscle complex I (NADH coenzyme Q reductase) deficiency. Ann Neurol 1988;24:749-56.
54. 54 Ciafaloni E, Ricci E, Shanske S, et al. MELAS. clinical features, biochemistry and molecular genetics. Ann Neurol 1992;31:391-8.
55. 55 Hammans SR, Sweeney MG, Brockington M, Morgan-Hughes JA, Harding AE. Mitochondrial encephalopathies: molecular genetic diagnosis from blood samples. Lancet 1991;337:1311-3,.
56. 56 De Vries D, de Wijs I, Ruitenbeek W, et al. Extreme variability of clinical symptoms among sibs in a MELAS family corrrelated with heteroplasmy for the mitochondrial A3243G mutation. J Neurol Sci 1994;124:77-82.
57. 57 Sakuta R, Nonaka I. Vascular involvement in mitochondrial myopathy. Ann Neurol 1989;25:594-601.
58. Leu (UUR) mutation at base pair 3243 of the mitochondrial DNA. Neurology 1995;45:1188-92.
59. 59 Hara H, Wakayama Y, Kouno Y, Yamada H, Tanaka M, Ozawa T. Acute peripheral neuropathy, rhabdomyolysis, and severe lactic acidosis associated with the 3243 A to G mitochondrial DNA mutation. J Neurol Neurosurg Psychiatry 1994;57:1545-6.
60. 60 Ishitsu T, Miike T, Kitano A, et al. Heterogenous phenotypes of mitochondrial encephalomyopathy in a single kindred. Neurology 1987;37:1867-9.
61. 61 Hasegawa H, Matsuoka T, Goto Y, Nonaka I. Strongly succinate dehydrogenase-reactive blood vessels in muscles from patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Ann Neurol 1991;29:601-5.
62. 62 Lertrit P, Noer AS, Jean-Francois MJB, et al. A new disease related mutation for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome affects the ND4 subunit of the respiratory complex I. Am J Hum Genet 1992;51:457-68.
63. (3243) mutation: a clinical and genetic study. Brain 1995;118:721-34.
64. 64 Morten KJ, Cooper JM, Brown GK, Lake BD, Pike D, Poulton J. A new point mutation associated with mitochondrial encephalomyopathy. Hum Mol Genet 1993;2:2081-7.
65. Leu (UUR) gene introduced from a MELAS patient to HeLa cells lacking mtDNA results in progressive inhibition of mitochondrial respiratory function. Biochem Biophys Res Commun 1993;197:1049-55.
66. 66 Campos Y, Garcia-Silva T, Barrionuevo CR, Cabello A, Muley R, Arenas J. Mitochondrial DNA deletion in a patient with mitochondrial myopathy, lactic acidosis and stroke-like episodes (MELAS) and Fanconi's syndrome. Pediatr Neurol 1995;13:69-72.
67. 67 Kadowaki T, Kadowaki H, Mori Y, et al. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 1994;330:962-8.
68. 68 Mariotti C, Saverese N, Suomalainen A, et al. Genotype to phenotype correlations in mitochondrial encephalomyopathies associated with the A3423G mutation of mitochondrial DNA. J Neurol 1995;242:304-12.
69. 69 Tsaris P, Engel WK, Kark P. Familial myoclonic epilepsy syndrome associated with skeletal muscle mitochondrial abnormalities. Neurology 1973;23:408.
70. 70 Fukuhara N, Tokiguchi S, Shirakawa K, Tsubaki T. Myoclonic epilepsy associated with ragged-red fibres (mitochondrial abnormalities): disease entity or a syndrome? J Neurol Sci 1980;47:117-33.
71. 71 Rosing HS, Hopkins LC, Wallace DC, Epstein CM, Weidenheim K. Maternally inherited mitochondrial myopathy and myoclonic epilepsy. Ann Neurol 1985;17:228-37.
72. Lys mutation. Cell 1990;61:931-7.
73. 73 Zeviani M, Amati P, Bresolin N, et al. Rapid detection of the A_13Monotype SortsG 8344 mutation of mtDNA in Italian families with myoclonic epilepsy and ragged-red fibres (MERRF). Am J Hum Genet 1991;48:203-11.
74. 74 Morgan-Hughes JA, Hayes DJ, Clark JB, et al. Mitochondrial encephalomyopathies: biochemical studies in two cases revealing defects in the respiratory chain. Brain 1982;105:553-82.
75. 75 Fukuhara N. Stroke like episodes in MERRF. Ann Neurol 1985;18:368.
76. 76 Lombes A, Mendell JR, Nakase H, et al. Myoclonic epilepsy and ragged-red fibres with cytochrome oxidase deficiency: neuropathology, biochemistry and molecular genetics. Ann Neurol 1989;26:20-33.
77. 77 Wallace DC, Zheng X, Lott MT, et al. Familial mitochondrial encephalomyopathy (MERRF): genetic, pathophysiological and biochemical characterization of a mitochondrial DNA disease. Cell 1988;55:601-10.
78. (8334) mutation and the syndrome of myoclonic epilepsy with ragged-red fibres. Brain 1993;116:617-32.
79. 79 Hanna MG, Nelson IP, Morgan-Hughes JA, Harding AE. Impaired mitochondrial translation in human myoblasts harbouring the mitochondrial DNA tRNA lysine 8344 A to G (MERRF) mutation: relationship to proportion of mutant mitochondrial DNA. J Neurol Sci 1995;130:154-60.
80. Lys gene associated with myoclonic epilepsy and ragged-red fibres (MERRF). Am J Hum Genet 1992;51:1213-7.
81. 81 Moraes CT, Ciacci F, Bonilla E, et al. Two novel pathogenic mitochondrial DNA mutations affecting organelle number and protein synthesis. J Clin Invest 1993;92:2906-15.
82. 82 Ionasescu V. Oculogastrointestinal muscular dystrophy. Am J Med Genet 1983;S15:103-12.
83. 83 Bardosi A, Creutzfeldt W, DiMauro S, et al. Myo-, neuro-, gastrointestinal encephalopathy (MNGIE) syndrome due to partial deficiency of cytochrome c oxidase. A new mitochondrial multisystem disorder. Acta Neuropathol 1987;74:248-58.
84. 84 Hirano M, Silvestri G, Blake DM, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondiral disorder. Neurology 1994;44: 721-7.
85. 85 Li V, Hostein J, Romero NB, et al. Chronic intestinal pseudoobstruction with myopathy and ophthalmoplegia. A muscular biochemical study of a mitochondrial disorder. Digest Dis Sci 1992;37:456-63.
86. 86 Simon LT, Horoupian DS, Dorfman LJ, et al. Polyneuropathy, ophthalmoplegia, leukoencephalopathy and intestinal pseudoobstruction: POLIP syndrome. Ann Neurol 1990;28:349-60.
87. 87 Silvestri G, Rana M, Servidei S, et al. A 1 base pair deletion in the tRNAThr gene pf mtDNA. a new mutation associated with mitochondrial myo-neuro-gastrointestinal encephalomyopathy (MNGIE). Neurology 1995;45:A244.
88. 88 Imai Y, Moriwaki D. A probable case of cytoplasmic inheritance in man: a critique of Leber's disease. J Genet Hum 1936;3:163-7.
89. 89 Nikoskelainen EK, Hoyt WF, Nummelin KU. Ophthalmoscopic findings in Leber's hereditary optic neuropathy II. The fundus findings in the affected family members. Arch Ophthalmol 1983;101:1059-68.
90. 90 Newman NJ, Lott MT, Wallace DC. The clinical charateristics of cedigrees of Leber's hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol 1991;111:750-62.
91. 91 Riordan-Eva P, Sanders M, Govan GG, Sweeney MG, Da Costa J, Harding AE. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain 1995;118:319-37.
92. 92 Oostra R, Bolhuis PA, Wijberg FA, Zorn-Ende G, Bleeker-Wagermakers EM. Leber's hereditary optic neuropathy: correlations between mitochondrial genotype and visual outcome. J Med Genet 1991;31:280-6.
93. 93 Carroll WM, Mastalgia FL. Leber's optic neuropathy: a clinical and visual evoked potential study of affected and asymptomatic members of a six generation family. Brain 1979;102:559-80.
94. 94 Nikoskelainen EK, Sogg RL, Rosenthal AR, Friberg TR, Dorfman LJ. The early phase in Leber hereditary optic atrophy. Arch Ophthalmol 1977;95:969-78.
95. 95 Nikoskelainen EK, Hoyt WF, Nummelin KU. Opthalmoscopic findings in Leber's hereditary optic neuropathy. I. Fundus findings in asymptomatic family members. Arch Ophthalmol 1982;100:1597-602.
96. 96 Howell N, McCullough D, Bodis-Wollner I. Molecular genetic analysis of a sporadic case of Leber hereditary optic neuropathy. Am J Hum Genet 1994;50:443-6.
97. 97 Weiner NC, Newman NJ, Lessell S, Johns DR, Lott MT, Wallace DC. Atypical Leber's hereditary optic neuropathy with molecular confirmation. Arch Neurol 1993;50:470-3.
98. 98 Harding AE, Sweeney MG, Miller DH, et al. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 1992;115:979-89.
99. 99 Wallace DC. A new manifestation of Leber's disease and a new explanation for the agency responsible for its unusual pattern of inheritance. Brain 1970;93:121-32.
100. 100 Newman NJ. Leber's hereditary optic neuropathy: new genetic considerations. Arch Neurol, 1993;50:540-8.
101. 101 Johns DR, Smith KH, Savino PJ, Miller NR. Leber's hereditary optic neuropathy: clinical manifestations of the 15257 mutation. Ophthalmology, 1993;100:981-6.
102. 102 Funakawa I, Kato H, Terao A, et al. Cerebellar ataxia in patients with Leber's hereditary optic neuropathy. J Neurol, 1995;242:75-7.
103. 103 Jun AS, Brown MD, Wallace DC. A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. Proc Natl Acad Sci USA, 1994;91:6206-10.
104. 104 Nikoskelainen EK, Marttila RJ, Huoponen K, et al. Leber's 'plus': neurological abnormalities in patients with Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry, 1995;59:160-4.
105. 105 Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science, 1988;242:1427-30.
106. 106 Huoponen K, Vilkki J, Aula P, Nikoskelainen EK, Savontaus M. A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy. Am J Hum Genet 1991;48:1147-53.
107. 107 Johns DR, Neufeld MJ, Park RD. An ND6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. Biochem Biophys Res Commun, 1992;187:1551-7.
108. 108 Hely MA, Morris JGL, Reid WGJ, et al. The Sydney multicentre study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry, 1994;57:903-10.
109. 109 Howell N, Kubacka I, Xu M, McCullough DA. Leber hereditary optic neuropathy: involvement of the mitochondrial ND1 gene and evidence for an intragenic suppressor mutation. Am J Hum Genet, 1991;48:935-42.
110. 110 Oostra R, Bolhuis PA, Zorn-Ende I, de Kok-Nazaruk MM, Bleeker-Wagermakers EM. Leber's hereditary optic neuropathy: no significant evidence for primary or secondary pathogenicity of the 15257 mutation. Hum Genet 1994;94:265-70.
111. 111 Mackey DA. Three subgroups of patients from the united kingdom with Leber hereditary optic neuropathy. Eye, 1994;8:431-6.
112. 112 Harding AE, Sweeney MG, Govan GG, Riordan-Eva P. Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation. Am J Hum Genet, 1995;57:77-86.
113. 113 Bu X, Rotter JI. X chromosome-linked and mitochondrial gene control of Leber hereditary optic neuropathy: evidence from segregation analysis for dependence on X chromosome inactivation. Proc Natl Acad Sci USA, 1991;88:8198-202.
114. 114 Chen J, Cox I, Denton MJ. Preliminary exclusion of an X-linked gene in Leber optic atrophy by linkage analysis. Hum Genet, 1989;82:203-7.
115. 115 Pallini R, Frederico A, Manneschi L, Azzunziata P, De Stefano N, Dotti MT. Is Leber's hereditary optic neuropathy a mitochondrial disease? Clinical, biochemical and histological study of several families. J Neurol, 1988;235:S7.
116. 116 Govan GG, Smith PR, Kellar-Wood H, Schapira AHV, Harding AE. HLA class II genotypes in Leber's hereditary optic neuropathy. J Neurol Sci, 1994;126:193-6.